Insider Trading March 24, 2026

Amprius Technologies Director Sells $4.1M in Stock as Company Posts Strong Q4 Results

Director Sun Kang executed two transactions for 217,869 shares under a pre-arranged 10b5-1 plan; Amprius reported better-than-expected Q4 results and secured new customer wins and contract expansions

By Caleb Monroe AMPX
Amprius Technologies Director Sells $4.1M in Stock as Company Posts Strong Q4 Results
AMPX

Sun Kang, a director at Amprius Technologies (NASDAQ: AMPX), sold 217,869 shares on March 23, 2026, in two transactions totaling about $4.1 million. The trades were completed under a Rule 10b5-1 plan adopted in August 2025. The company reported fourth-quarter 2025 results that beat expectations, recorded record quarterly revenue, added over 100 customers, and expanded key contracts, while shares have pulled back roughly 8% from their 52-week high.

Key Points

  • Director Sun Kang sold 217,869 Amprius shares on March 23, 2026, in two transactions totaling about $4.1 million.
  • Amprius beat Q4 2025 expectations with EPS of -$0.01 and record quarterly revenue of $25.2 million; research firms raised price targets.
  • Company added over 100 new customers, secured a contract with Nokia Drone Networks, and expanded a Defense Innovation Unit contract from $10.5 million to $14.8 million - relevant to drone and defense sectors.

Director Sun Kang of Amprius Technologies (NASDAQ: AMPX) disposed of 217,869 shares of common stock on March 23, 2026, across two separate trades, for an aggregate value of approximately $4.1 million.

The sales were executed at weighted average prices spanning $17.89 to $19.36 per share. The first transaction accounted for 152,823 shares sold at an average price of $18.6863. The second transaction involved 65,046 shares sold at an average price of $19.0589. The reported volume and pricing place the combined proceeds near $4.1 million.

Following these transactions, Sun Kang continues to hold equity positions in Amprius both directly and indirectly. Indirect holdings include 177,858 shares held through the KANG & CECILLIA SUN FAMILY REVOCABLE TRUST. Direct holdings total 1,342,400 shares, which include 1,159,385 restricted stock units.

The reported trades were carried out under a pre-arranged Rule 10b5-1 trading plan that the director adopted on August 18, 2025.


These insider sales come as Amprius shares have experienced significant appreciation over the past year, delivering a 438% return year-over-year, though the stock has eased by about 8% in the past week from its 52-week high of $19.76.

On the operational and financial front, Amprius disclosed fourth-quarter 2025 results that outperformed analyst expectations. The company posted an earnings per share (EPS) of negative $0.01, which was better than the forecasted negative $0.05. Revenue for the quarter reached a record $25.2 million, topping the anticipated $24.5 million.

Market participants and research firms responded to the quarterly results with upward revisions to price targets. Craig-Hallum lifted its price target on Amprius from $17 to $21 and maintained a Buy rating. Cantor Fitzgerald raised its price target from $16 to $20, citing strong execution against growing demand.

Amprius also reported commercial and government wins in recent periods. The company said it added more than 100 new customers and secured a material contract with Nokia Drone Networks. In the government arena, Amprius expanded its Defense Innovation Unit contract from $10.5 million to $14.8 million.

Separately, Kensington Capital Acquisition Corp. VI completed its $230 million initial public offering on the New York Stock Exchange.


The combination of notable insider selling, a highly volatile share performance over the prior year, and recent operational progress sets a mixed backdrop for investors evaluating Amprius. The company has reported improved results and contract wins, while an ongoing negative EPS and short-term price pullback reflect continuing transition dynamics for the business.

Risks

  • Shares have pulled back roughly 8% in the past week from a 52-week high of $19.76, indicating short-term price volatility - relevant to public markets and investor sentiment.
  • The company reported a negative EPS of $0.01 for Q4 2025, highlighting ongoing losses despite revenue growth - relevant to equity valuation and capital markets.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026